Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / Aurisco Pharmaceutical
Entity

Aurisco Pharmaceutical

Tracked across 1 events · 7 articles · First seen Aug 12, 2026 · Last active Aug 12, 2026

Sentiment
80
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
4 80
Regulatory
Aurisco passes USFDA generic oligonucleotide inspection
Aurisco Pharmaceutical, a Chinese manufacturer of oligonucleotides and peptides, announced that its Yangzhou site passed a USFDA pre-approval inspection for Inclisiran Sodium, making it the first generic oligonucleotide API manufacturer in the world to receive…
Impact: Aurisco is the central entity, achieving a world-first USFDA approval for generic oligonucleotide manufacturing, which enhances its reputation and market prospects.
Aug 12, 2026 · 7 articles
Key Actions (1)
100 United States — Food and Drug Administration inspected Aurisco PharmaceuticalAurisco passes USFDA...
ERGEN INTELLIGENCE
Track Aurisco Pharmaceutical live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.